Medsamic (Tranexamic Acid)

Tranexamic Acid is an antifibrinolytic used to control bleeding in several clinical situations.

• Surgical bleeding: Reduces intra‑operative and postoperative blood loss, facilitating hemostasis.
• Trauma‑related hemorrhage: Controls acute bleeding following traumatic injury.
• Menorrhagia: Decreases menstrual blood loss in women with heavy periods.
• Hemophilia‑related bleeding: Assists in managing bleeding episodes in patients with hemophilia.
• Hereditary angioedema: Helps prevent or limit swelling episodes associated with HAE.

• Tranexamic Acid competitively inhibits the activation of plasminogen to plasmin by binding to the lysine‑binding sites on plasminogen molecules. By blocking this conversion, fibrin degradation is reduced, leading to stabilization of formed clots and decreased bleeding. The drug does not affect platelet function and works systemically after intravenous administration. Its effect is dose‑dependent and persists while plasma concentrations remain above the inhibitory threshold, providing sustained hemostatic support during surgical or traumatic events.

Tranexamic Acid may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Nausea
• Vomiting
• Headache

Serious or Rare Side Effects

• Thromboembolic events (deep vein thrombosis, pulmonary embolism)
• Severe hypotension
• Allergic reactions (rash, urticaria, anaphylaxis)

When using Tranexamic Acid, clinicians should observe several precautionary measures to minimise risk.

• Renal impairment: Adjust dose or monitor plasma levels in patients with reduced kidney function.
• History of thrombosis: Avoid use in individuals with recent or active thromboembolic disease.
• Pregnancy: Use only if potential benefit justifies potential risk, as safety data are limited.
• Concomitant procoagulant therapy: Evaluate risk when combined with hormonal contraceptives or estrogen therapy.
• Anticoagulant therapy: Monitor coagulation parameters closely if used alongside warfarin, heparin, or DOACs.
• Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Tranexamic Acid can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid)

• Thrombolytic agents (e.g., alteplase, streptokinase): May antagonise clot‑dissolving action.
• Combined hormonal contraceptives or estrogen therapy: Increases risk of thromboembolic events.
• Other antifibrinolytics (e.g., epsilon‑aminocaproic acid): Excessive inhibition of fibrinolysis.

Moderate Interactions (Monitor Closely)

• Anticoagulants (warfarin, DOACs): May require dose adjustment and coagulation monitoring.
• NSAIDs (ibuprofen, aspirin): Potential additive effect on bleeding risk.
• Antiplatelet agents (clopidogrel, ticagrelor): Monitor for altered hemostasis.